Skip to main content
OpenTrials
Completed

NCT Number: NCT00225745

Ghrelin Levels in Pancreatic Cancer Patients

The primary outcome measure for this study is plasma ghrelin level.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center

Lebanon, New Hampshire, 03756, United States

About this study

The primary outcome measure for this study is plasma ghrelin level, and the two primary comparison are:

  • Patients with cachexia versus patients without cachexia
  • Patients with cachexia versus healthy controls

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histological or cytological proof of pancreatic adenocarcinoma
  • The control are will include healthy age-matched patients without cancer
  • The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss
  • Patients must have recovered from any major infections and/or surgical procedures

Exclusion criteria

  • Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state
  • Patients on appetite stimulant and those receiving total parenteral nutrition
  • Patients who have undergone gastrectomy or those who have gastric ulcers
  • Patients receiving active chemotherapy
  • No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.

Treatment and study plan

Blood draw

Procedure

One blood draw prior to first treatment

Primary outcomes

  1. To evaluate plasma ghrelin levels in patients with pancreatic cancer and compare with age matched controls

    Time frame: prior to treatment

Secondary outcomes

  1. To investigate the role of ghrelin in pathophysiology of cancer cachexia

    Time frame: prior to treatment

  2. To generate hypotheses for future studies and treatment based on the findings

    Time frame: prior to treatment

Sponsors and collaborators

Lead sponsor

Dartmouth-Hitchcock Medical Center

Other

Registry information

Official study title

Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer

Important dates

Study start
2004
Primary completion
2013
Study completion
2015
First posted
Sep 26, 2005
Registry last updated
Oct 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.